Osteogenic Activity of Locally Applied Small Molecule Drugs in a Rat Femur Defect Model

The long-term success of arthroplastic joints is dependent on the stabilization of the implant within the skeletal site. Movement of the arthroplastic implant within the bone can stimulate osteolysis, and therefore methods which promote rigid fixation or bone growth are expected to enhance implant s...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2010-01, Vol.2010 (2010), p.1-11
Main Authors: Cottrell, Jessica A., Vales, Francis M., Schachter, Deborah, Wadsworth, Scott, Gundlapalli, Rama, Kapadia, Rasesh, O'Connor, J. Patrick
Format: Article
Language:English
Subjects:
Alendronate - pharmacology
Animals
Apoptosis
Biocompatibility
Biological and medical sciences
Biomedical materials
Biotechnology
Bone density
Bone Density - drug effects
Bones
Defects
Disease Models, Animal
Drugs
Femur - diagnostic imaging
Femur - drug effects
Femur - pathology
Femur - surgery
Hydrogels
Joint surgery
Lovastatin - pharmacology
Male
Medical sciences
Methods
Omeprazole - pharmacology
Organ Size - drug effects
Osteogenesis - drug effects
Osteoporosis
Pharmacology. Drug treatments
Rats
Rats, Sprague-Dawley
Stabilization
Studies
Surgical implants
Wound Healing - drug effects
X-Ray Microtomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The long-term success of arthroplastic joints is dependent on the stabilization of the implant within the skeletal site. Movement of the arthroplastic implant within the bone can stimulate osteolysis, and therefore methods which promote rigid fixation or bone growth are expected to enhance implant stability and the long-term success of joint arthroplasty. In the present study, we used a simple bilateral bone defect model to analyze the osteogenic activity of three small-molecule drug implants via microcomputerized tomography (micro-CT) and histomorphometry. In this study, we show that local delivery of alendronate, but not lovastatin or omeprazole, led to significant new bone formation at the defect site. Since alendronate impedes osteoclast-development, it is theorized that alendronate treatment results in a net increase in bone formation by preventing osteoclast mediated remodeling of the newly formed bone and upregulating osteoblasts.
ISSN:1110-7243
2314-6133
1110-7251
2314-6141
DOI:10.1155/2010/597641